Feedback: January 2024
feedback_jan2024.RmdOverview
The R Consortium Submissions Working Group meets monthly to discuss progress on the various pilots being submitted to the FDA as well as receive feedback from the FDA reviewers. Pilot 3 was submitted in October 2023 and has started to receive feedback from the reviewers.
The following is a summary of the January 2024 meeting that pertains to the Pilot 3 Submission
The FDA Review indicated that using the R generated ADaM data sets in Pilot3, the reviewers were able to replicate the results of the four analyses used in Pilot 1. The FDA Reviewer (Hye Soo) did identify (so far) several issues and presented observations and questions for response from the Pilot3 Team.
Items [1] through [3] are Actionable. Items [4] and [5] are Non-Actionable.
Item 1
- FDA Reviewer observed no statistical analysis plan (SAP) was included with the Pilot3 submission.
Action Item: Confirm with FDA Reviewers that the SAP should be included if a re-submission is requested. Given Question 1(b) inclusion of the SAP may provide clarity regarding correctness.
Item 2
- The Primary output in Pilot 3 was different from the Pilot 1 result due to the QC findings. QC findings in the ADRG include all of the discrepancies between the original ADaM datasets.
Action Item: Respond to FDA Review Question #1: How did you know this was an issue from the CDISC ADADAS (Pilot1) and how did you correct them? FDA Reviewer shared an example using USUBJID 01-705-1292
Question 1(a): Why was LOCF required when there was no missing data in the QS?
Observation: FDA Reviewer (Hye Soo) noted in the primary results (i)slight difference in rounding and (ii)quite different p-values. [Appears to be due to QC Findings discrepancies.] Action Item: Respond to FDA Review Question 1(b): Which primary analysis output is correct? Hye Soo noted lack of clarity regarding determination of correctness due to unavailable SAP.
Item 3
- FDA Review also presented an observation noting that in the Pilot3 Summary Tables and Figures Report you noted that different open-source packages were used when generating each of the 4 analysis outputs to test wider use case scenarios. However, the R packages and scripts seem identical to Pilot1.
Action Item: Respond to FDA Review Question #2: What exactly has changed? *This was discussed at the R Consortium WG and Ning responded to the question by stating the language used in the Pilot3 submission was carried over from Pilot1 to Pilot3. The Pilot3 response should confirm Ning’s response to Hye Soo.